Synopsis
Chimeric antigen receptor (CAR) T-cell therapy shows significant potential in treating various human cancers. Unfortunately, researchers have faced difficulty in adapting this therapy to target solid tumors, where CAR T cells face unique challenges, such as antigen heterogeneity, an immuno-suppressive microenvironment, and T-cell exhaustion.
However, none of these challenges matter unless the CAR T cells can extravasate out of the blood stream and successfully migrate to the site of the tumor—an often-overlooked yet critical rate-limiting part of the process that cannot be modeled in conventional cell cultures.
To address this, Emulate has recently launched a validated Organ-Chip workflow enabling researchers to model the entire journey of solid tumor CAR T-cell therapy in a vascularized cancer cell line model.
Join us May 16th as Emulate Principal Scientist Anita Mehta, PhD, demonstrates the capabilities of this new CAR T Organ-Chip workflow in a data-driven webinar. Researchers will learn how to use Organ-Chips to model CAR T-cell therapy administration, vascular attachment, migration, and antigen-specific killing—all in a single model. Additionally, Luke Dimasi, Sr. Director of Product Management, will provide an overview of Emulate Organ-on-a-Chip technology and how it can be used to faithfully model the complexities of human biology across a variety of applications.
In this webinar, participants will learn about:
- Emulate Organ-on-a-Chip technology and its applications in disease research and drug development.
- Modeling CAR T-cell recruitment and solid tumor cell killing in a unified Organ-Chip assay.
- Evaluating co-therapeutics to enhance CAR T recruitment and killing efficiency.
- Conducting comprehensive CAR T efficacy analysis through techniques such as confocal imaging with automated quantification, effluent analysis of cytokine release, and immune cell extraction and phenotyping.
